150 related articles for article (PubMed ID: 37415400)
1. Metastatic Translocated Renal Cell Carcinoma in a Kidney Transplant Patient - a Case Report and Review of the Literature.
Kläger J; Schmidinger M; Oszwald A; Wasinger G; Fajkovic H; Compérat E
Int J Surg Pathol; 2024 May; 32(3):594-600. PubMed ID: 37415400
[No Abstract] [Full Text] [Related]
2. TFEB-amplified Renal Cell Carcinomas: An Aggressive Molecular Subset Demonstrating Variable Melanocytic Marker Expression and Morphologic Heterogeneity.
Argani P; Reuter VE; Zhang L; Sung YS; Ning Y; Epstein JI; Netto GJ; Antonescu CR
Am J Surg Pathol; 2016 Nov; 40(11):1484-1495. PubMed ID: 27565001
[TBL] [Abstract][Full Text] [Related]
3. Eosinophilic solid and cystic renal cell carcinoma and renal cell carcinomas with TFEB alterations: a comparative study.
Lobo J; Rechsteiner M; Helmchen BM; Rupp NJ; Weber A; Moch H
Histopathology; 2022 Jul; 81(1):32-43. PubMed ID: 35403742
[TBL] [Abstract][Full Text] [Related]
4. Histological and molecular characterization of TFEB-rearranged renal cell carcinomas.
Wyvekens N; Rechsteiner M; Fritz C; Wagner U; Tchinda J; Wenzel C; Kuithan F; Horn LC; Moch H
Virchows Arch; 2019 May; 474(5):625-631. PubMed ID: 30706129
[TBL] [Abstract][Full Text] [Related]
5. Translocation carcinomas of the kidney.
Argani P
Genes Chromosomes Cancer; 2022 May; 61(5):219-227. PubMed ID: 34704642
[TBL] [Abstract][Full Text] [Related]
6. Aggressive and nonaggressive translocation t(6;11) renal cell carcinoma: comparative study of 6 cases and review of the literature.
Peckova K; Vanecek T; Martinek P; Spagnolo D; Kuroda N; Brunelli M; Vranic S; Djuricic S; Rotterova P; Daum O; Kokoskova B; Vesela P; Pivovarcikova K; Bauleth K; Dubova M; Kalusova K; Hora M; Michal M; Hes O
Ann Diagn Pathol; 2014 Dec; 18(6):351-7. PubMed ID: 25438924
[TBL] [Abstract][Full Text] [Related]
7. Prognosis and Clinicopathological Characters of Adult TFEB-Altered Renal Cell Carcinoma: A Single Center Experience of 18 Cases.
Wu J; Cao CZ; Cui HL; Du G; Shi HZ; Liang J; Guo L; Wang YC; Zhang J; Zhou AP; Li CL; Zheng S; Shou JZ
Clin Genitourin Cancer; 2024 Apr; 22(2):261-268.e3. PubMed ID: 38104031
[TBL] [Abstract][Full Text] [Related]
8. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ
Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969
[TBL] [Abstract][Full Text] [Related]
9. Merlin immunohistochemistry is useful in diagnosis of tumours within the spectrum of biphasic hyalinizing psammomatous renal cell carcinoma.
Collins K; Hwang M; Antic T; Paintal A; Argani P; Matoso A; Gopinath A; Baskovich B; Mehra R; Williamson SR; Idrees MT; Barletta JA; Anderson WJ; Hirsch MS; Hornick JL; Acosta AM
Histopathology; 2022 Nov; 81(5):577-586. PubMed ID: 35971742
[TBL] [Abstract][Full Text] [Related]
10. Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays.
Skala SL; Xiao H; Udager AM; Dhanasekaran SM; Shukla S; Zhang Y; Landau C; Shao L; Roulston D; Wang L; Siddiqui J; Cao X; Magi-Galluzzi C; Zhang M; Osunkoya AO; Smith SC; McKenney JK; Betz BL; Myers JL; Chinnaiyan AM; Tomlins SA; Mehra R
Mod Pathol; 2018 Jan; 31(1):179-197. PubMed ID: 28840857
[TBL] [Abstract][Full Text] [Related]
11. t(6;11)(p21;q12)/TFEB gene fusion-associated renal cell carcinoma: a case report and review of literature.
Ma J; Wang Y; Liu Y; Li P
Int J Clin Exp Pathol; 2017; 10(8):8773-8776. PubMed ID: 31966741
[TBL] [Abstract][Full Text] [Related]
12. Spectrum of biphasic renal cell carcinomas with hyalinized stroma and psammoma bodies associated and not associated with NF2 alteration.
Chumbalkar V; Wang P; Paner GP
Hum Pathol; 2022 Mar; 121():11-18. PubMed ID: 34929230
[TBL] [Abstract][Full Text] [Related]
13. t(6;11) renal cell carcinoma: a study of seven cases including two with aggressive behavior, and utility of CD68 (PG-M1) in the differential diagnosis with pure epithelioid PEComa/epithelioid angiomyolipoma.
Caliò A; Brunelli M; Segala D; Pedron S; Tardanico R; Remo A; Gobbo S; Meneghelli E; Doglioni C; Hes O; Zampini C; Argani P; Martignoni G
Mod Pathol; 2018 Mar; 31(3):474-487. PubMed ID: 29052596
[TBL] [Abstract][Full Text] [Related]
14. [Renal cell carcinoma with t(6;11)(p21.2;q13)/MALAT1-TFEB fusion: a clinical and pathological analysis].
Xia Q; Shi S; Shen Q; Wei X; Wang X; Ma H; Lu Z; Zhou X; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2015 Dec; 44(12):895-9. PubMed ID: 26888508
[TBL] [Abstract][Full Text] [Related]
15. A Tale of 2 Morphologies: Diagnostic Pitfalls in
Sharma AE; Parilla M; Wanjari P; Segal JP; Antic T
Int J Surg Pathol; 2021 Feb; 29(1):21-29. PubMed ID: 32886007
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders.
Boilève A; Carlo MI; Barthélémy P; Oudard S; Borchiellini D; Voss MH; George S; Chevreau C; Landman-Parker J; Tabone MD; Chism DD; Amin A; Bilen MA; Bosse D; Coulomb-L'hermine A; Su X; Choueiri TK; Tannir NM; Malouf GG
J Immunother Cancer; 2018 Dec; 6(1):159. PubMed ID: 30591082
[TBL] [Abstract][Full Text] [Related]
17. TFEB Rearranged Renal Cell Carcinoma: Pathological and Molecular Characterization of 10 Cases, with Novel Clinical Implications: A Single Center 10-Year Experience.
Wang AX; Tian T; Liu LB; Yang F; He HY; Zhou LQ
Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830782
[TBL] [Abstract][Full Text] [Related]
18. Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.
Wiele AJ; Bathala TK; Hahn AW; Xiao L; Duran M; Ross JA; Jonasch E; Shah AY; Campbell MT; Msaouel P; Tannir NM
Oncologist; 2021 Jun; 26(6):476-482. PubMed ID: 33792094
[TBL] [Abstract][Full Text] [Related]
19. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
[TBL] [Abstract][Full Text] [Related]
20. Case Report: Successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma.
Ratanasrimetha P; Reddy VD; Kala J; Tchakarov A; Glass WF; Msaouel P; Lin JS
Front Immunol; 2022; 13():898811. PubMed ID: 35967405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
